Multiple coagulation test device and method

• US 5,366,869 A
• Filed: 11/08/1991
• Issued: 11/22/1994
• Est. Priority Date: 11/08/1991
• Status: Expired due to Term

• Current Assignee: Coagulation Sciences LLC
• Original Assignee: Sheldon Goldstein
• Inventors: Goldstein, Sheldon
• Primary Examiner(s): NOT, DEFINED
• Assistant Examiner(s): Larson, K.
• Application Number:
  US07/790,631
• Time in Patent Office: 1,110 Days
• Field of Search: 424/93 A, 424/93 B, 424/93 C, 424/93 D, 424/93 E, 424/94.64, 424/93 W, 424/530, 424/532, 435/29, 435/13, 514/21, 514/2, 514/12, 514/464, 514/561, 514/802, 514/834, 436/16
• US Class Current: 435/13
• CPC Class Codes: C12Q 1/56 involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
• CPC Class Codes: G01N 33/4905 Determining clotting time of blood by chemical methods G01N33/86, C12Q1/56
• CPC Class Codes: Y10T 436/106664 Blood serum or blood plasma standard or control

Abstract

A multiple coagulation test device has a plurality of tubes, each tube having associated coagulation detection means, and containing a treatment dosage of a coagulation enhancing agent. Whole blood samples are placed in the tubes which are mixed and warmed to 37° C., with the time to coagulation determined. The agent giving the lowest clotting time is selected as the most effective treatment for reducing hemorrhaging within a few minutes and the selected treatment begun. Utilizing the inventive device eliminates the need to use a multiple agent approach, by identifying the most effective course of action.

Claims

1. A method for determining the treatment required to arrest hemorrhaging in a patient comprising

a) providing a series of different agents capable of enhancing blood clotting;

b) obtaining a series of samples of the patient'"'"'s blood;

c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent;

d) simultaneously measuring the clotting time for each mixture in said series; and

e) selecting the agent in said series which produces the most rapid clotting time.

2. The method of claim 1 wherein the blood clotting enhancing agent is selected from the group consisting of coagulation factors, platelets, plasminogen activator, desmopressin acetate (DDAVP), epsilo-amino caproic acid, protamine, aprotinin, fibronectin, thrombin, plasminogen, plasma, a cryoprecipitated plasma product and prostacyclin.

3. The method of claim 2 wherein the coagulation factor is coagulation factor I (fibrinogen), Ia (fibrin), II (prothrombin), IIa (thrombin), III (thromboplastin), IV, V, VI, VII, VIII, IX, X, XI, XII, VIII:

C, von Willebrand factor or a bovine coagulation factor.

4. The method of claim 2 wherein the plasma is bovine plasma, or human fresh frozen plasma.

5. A method for arresting hemorrhaging in a patient comprising

a) providing a series of different agents capable of enhancing blood clotting;

b) obtaining a series of samples of the patient'"'"'s blood;

c) mixing a sample of blood with each of the individual agents to prepare a series of mixtures, each mixture of said series containing a different agent;

d) simultaneously measuring the clotting time for each mixture in said series;

e) selecting the agent in said series which produces the most rapid clotting time; and

f) administering a blood clotting effective amount of the selected agent from step e) to the patient.

6. The method of claim 5 wherein the blood clotting enhancing agent is selected from the group consisting of coagulation factors, platelets, plasminogen activator, desmopressin acetate (DDAVP), epsilo-amino caproic acid, protamine, aprotinin, fibronectin, thrombin, plasminogen, plasma, a cryoprecipitated plasma product and prostacyclin.

7. The method of claim 6 wherein the coagulation factor is coagulation factor I (fibrinogen), Ia (fibrin), II (prothrombin), IIa (thrombin), III (thromboplastin) IV, V, VI, VII, VIII, IX, X, XI, XII, VIII:

C, von Willebrand factor or a bovine coagulation factor.

8. The method of claim 6 wherein the plasma is bovine fresh frozen plasma, or human plasma.